Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daiichi Sankyo Company, a Japan-based holding company engaged in the manufacture and sale of pharmaceuticals, and its subsidiary Daiichi Sankyo Propharma have announced the closure of the Osaka plant of Daiichi Sankyo Propharma.
Subscribe to our email newsletter
The Daiichi Sankyo Group currently possesses four pharmaceutical formulation plants in Japan. The Osaka plant will be closed after comprehensive evaluation of the current product line, overseas market conditions, status of facilities, current and future production capability, and location among others to respond to the demand in 2015.
Production of main products at the Osaka plant will be transferred to other plants from October 2008 to March 2011 and other products will be outsourced. The plant will be closed in March 2011.
The Daiichi Sankyo Group is expanding its growth platform to meet the Vision for 2015 (sales of JPY1.5 trillion, operating income ratio of 25% or more and overseas sales ratio of 60% or more). The group is implementing an optimal global supply system in accordance with the Vision for 2015 to realize a stable global supply and to generate higher profit throughout the supply chain from production to distribution. Restructuring of Japanese domestic plants is one element of these efforts.